Anthos and Novartis initiate LILAC-TIMI 76 trial for abelacimab in high-risk AF patients
The LILAC-TIMI 76 study is evaluating abelacimab's efficacy and safety in high-risk atrial fibrillation patients unsuitable for oral anticoagulation.
Company
Pharmaceutical intelligence for Anthos Therapeutics with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.